Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH: Ramucirumab vs Placebo as Second-Line Therapy in Hepatocellular Carcinoma after Sorafenib
jRCT2080221281Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Ramucirumab + best supportive care with Placebo + best supportive care (2 arms).
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221281.